pentetic acid has been researched along with lewis y antigen in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Brechbiel, MW; Hudson, PJ; Lee, FT; Old, LJ; Power, BE; Renner, C; Scott, AM; Smyth, FE; Tahtis, K | 1 |
Brechbiel, MW; Burgess, AW; Hall, C; Johns, TG; Kelly, MP; Lee, FT; Mountain, AJ; Nice, EC; Rigopoulos, A; Scott, AM; Smyth, FE | 1 |
Brechbiel, MW; Kelly, MP; Lee, FT; Scott, AM; Smyth, FE; Tahtis, K | 1 |
3 other study(ies) available for pentetic acid and lewis y antigen
Article | Year |
---|---|
Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model.
Topics: Animals; Antibodies, Monoclonal; Antibody Affinity; Breast Neoplasms; Disease Models, Animal; Female; Gene Targeting; Humans; Immunoglobulin Fab Fragments; Indium Radioisotopes; Isothiocyanates; Lewis Blood Group Antigens; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Pentetic Acid; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Lewis Blood Group Antigens; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Pentetic Acid; Protein-Tyrosine Kinases; Quinazolines; Radioimmunotherapy; Radiopharmaceuticals; Signal Transduction; Time Factors; Tissue Distribution; Tyrphostins; Yttrium Radioisotopes | 2005 |
Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy.
Topics: Alpha Particles; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Apoptosis; Bismuth; Cell Line, Tumor; Combined Modality Therapy; Female; Humans; Immunoglobulin Fab Fragments; Isothiocyanates; Lewis Blood Group Antigens; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Pentetic Acid; Radioimmunotherapy; Radioisotopes; Survival Rate; Tissue Distribution; Xenograft Model Antitumor Assays | 2007 |